Recently, the 24th World Pharmaceutical Raw Materials China Exhibition (CPHI China 2026) concluded successfully at the Shanghai New International Expo Centre. As a highly influential flagship industry event in the Asia-Pacific region, this exhibition gathered global pharmaceutical industry resources and built a platform for business matchmaking and technological exchange. Laviana Pharma made a significant appearance with its core business advantages, adopting an exclusive private meeting model to deepen industry collaboration, successfully completing its exhibition journey with fruitful results.

It is understood that the total exhibition area of this year's event exceeded 250.000 square meters, bringing together over 3.700 high-quality exhibitors from 33 countries and regions worldwide, and receiving more than 110.000 domestic and international professional visitors. The exhibition launched six new themed zones, including the "Smart Laboratory Space," "International New Brand Zone," and "Drug-Device Combination Zone," injecting strong momentum into the collaborative development of the global pharmaceutical industry. The industry trend clearly points to a comprehensive shift from "scale competition" to "technology intensity" — cutting-edge technologies such as green intelligent manufacturing, AI-assisted drug discovery, continuous flow processes, and integrated CRDMO platforms became hot topics of discussion.

At this exhibition, Laviana Pharma set up an exclusive business meeting room, creating a quiet, private, and efficient one-on-one communication environment for domestic and international partners. During the exhibition, Laviana Pharma's professional team was stationed throughout the event, engaging in in-depth and productive consultations with new and existing global clients around core topics including API supply, formulation R&D collaboration, CDMO service capabilities, and global supply chain optimization. This customer-centric approach focused on solving substantive issues, greatly enhancing communication efficiency and receiving unanimous praise from visiting customers.

Currently, the pharmaceutical industry is undergoing transformation. Traditional CRDMO models, if lacking new technological support, will find it difficult to fully address the challenges of complex therapies. Leveraging its deep expertise in chemical synthesis, process development, and GMP production, Laviana Pharma continues to provide global clients with one-stop services from preclinical to commercialization. During this exhibition, the company highlighted its latest progress in complex API supply, formulation technology platforms, and global supply chain optimization, reaching preliminary cooperation intentions with several domestic and international pharmaceutical companies, further consolidating its strategic node position in the global CDMO network.

The successful conclusion of this exhibition would not have been possible without the trust and support of global partners. As Laviana Pharma anticipated before the exhibition, it looks forward to "discussing new business opportunities with global industry colleagues and opening a new chapter of win-win cooperation". In the future, Laviana Pharma will continue to strengthen its technological innovation system, expand its global service footprint, and help global clients accelerate the drug launch process with efficient, high-quality CDMO services.